These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1460166)

  • 1. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
    Möller HJ; Volz HP
    J Affect Disord; 1992 Nov; 26(3):163-72. PubMed ID: 1460166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
    Möller HJ; Volz HP
    Eur Neuropsychopharmacol; 1993 Dec; 3(4):501-10. PubMed ID: 8111223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression?
    Volz HP; Müller H; Möller HJ
    Neuropsychobiology; 1995; 32(1):23-30. PubMed ID: 7566519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brofaromine versus imipramine in in-patients with major depression--a controlled trial.
    Volz HP; Gleiter CH; Möller HJ
    J Affect Disord; 1997 Jul; 44(2-3):91-9. PubMed ID: 9241569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks.
    Volz HP; Müller H; Sturm Y; Preussler B; Möller HJ
    Psychiatry Res; 1995 Sep; 58(2):107-15. PubMed ID: 8570762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
    Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
    Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    J Affect Disord; 1994 Oct; 32(2):105-14. PubMed ID: 7829762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
    Rimón R; Jääskeläinen J; Kaartinen P; Kalli A; Kilponen E; Koskinen T; Nikkilä H; Pirttiperä V; Seppälä J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):141-7. PubMed ID: 8468435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():426A-427A. PubMed ID: 1498901
    [No Abstract]   [Full Text] [Related]  

  • 14. Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.
    Ucha Udabe R; Márquez CA; Traballi CA; Portes N
    Acta Psychiatr Scand Suppl; 1990; 360():54-6. PubMed ID: 2123367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.
    Hoencamp E; Haffmans PM; Dijken WA; Hoogduin CA; Nolen WA; van Dyck R
    J Affect Disord; 1994 Mar; 30(3):219-27. PubMed ID: 8006248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor--an open study.
    Delcker A; Gaertner HJ
    Eur Neuropsychopharmacol; 1991 May; 1(2):177-80. PubMed ID: 1821707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo- and imipramine-controlled study of paroxetine.
    Cohn JB; Crowder JE; Wilcox CS; Ryan PJ
    Psychopharmacol Bull; 1990; 26(2):185-9. PubMed ID: 2146697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
    Baumhackl U; Bizière K; Fischbach R; Geretsegger C; Hebenstreit G; Radmayr E; Stabl M
    Br J Psychiatry Suppl; 1989 Oct; (6):78-83. PubMed ID: 2695130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to assess the onset of antidepressant effect: comparison of global ratings and findings based on depression scales.
    Möller HJ; Müller H; Volz HP
    Pharmacopsychiatry; 1996 Mar; 29(2):57-62. PubMed ID: 8741022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.